Robert “Bob” Hombach is a member of the Board of Directors at Seaport and serves as the Chair of the Audit Committee. His three decades of experience include serving on the Audit, Finance and Compensation Committees for several public and private Boards of Directors, such as FORTUNE 500 companies like BioMarin (NASDAQ: BMRN), where he also chairs the Audit Committee, and Henry Schein (NASDAQ: HSIC), a member of the S&P 500® index.
Previously, he served as the Executive Vice President, Chief Financial Officer and Chief Operations Officer of Baxalta (NYSE: BXLT), a $6 billion global pharmaceutical company, until it was acquired by Shire plc. in 2016.
Mr. Hombach was instrumental in Baxalta’s successful spin off from its parent company, Baxter (NYSE: BAX), a nearly $18 billion company, where he previously served as Corporate Vice President and Chief Financial Officer. While at Baxter, he led the company’s strategic restructuring process and oversaw its venture capital investments through the Baxter Ventures Fund.
In addition to his board positions at BioMarin and Henry Schein, Mr. Hombach is the Chair of the Audit Committee at Embecta and has held previous board positions at several other companies including Naurex, Inc., which was acquired by Allergan in 2015.
What is Robert J. Hombach's net worth?
The estimated net worth of Robert J. Hombach is at least $287.43 thousand as of June 22nd, 2026. Mr. Hombach owns 13,000 shares of Seaport Therapeutics stock worth more than $287,430 as of June 29th. This net worth estimate does not reflect any other assets that Mr. Hombach may own. Learn More about Robert J. Hombach's net worth.
Has Robert J. Hombach been buying or selling shares of Seaport Therapeutics?
Over the course of the past ninety days, Robert J. Hombach has bought $235,820.00 of Seaport Therapeutics stock. Most recently, on Monday, June 22nd, Robert J. Hombach bought 13,000 shares of Seaport Therapeutics stock. The stock was acquired at an average cost of $18.14 per share, with a total value of $235,820.00. Following the completion of the transaction, the director now directly owns 13,000 shares of the company's stock, valued at $235,820. Learn More on Robert J. Hombach's trading history.
Are insiders buying or selling shares of Seaport Therapeutics?
In the last twelve months, Seaport Therapeutics insiders bought shares 2 times. They purchased a total of 1,113,000 shares worth more than $20,035,820.00. The most recent insider tranaction occured on June, 22nd when Director Robert J Hombach bought 13,000 shares worth more than $235,820.00.
Learn More about insider trades at Seaport Therapeutics. Information on this page was last updated on 6/22/2026.
